Literature DB >> 21436615

Met and the microenvironment: new insights for ovarian cancer metastasis.

Carole Sourbier1.   

Abstract

Ovarian cancer often has few symptoms, which makes it difficult to detect at an early stage. Therefore, most of the women will already have metastasis at the time of diagnosis. In their search of undercovering the mechanisms underlying ovarian cancer invasion, AK Mitra and collaborators demonstrate that the fibronectin receptor (α5β1-integrin) can directly activate the receptor tyrosine kinase Met, independently of its ligand. By linking the extracellular matrix with Met activation, and the invasion of ovarian cancer cells, Mitra et al confirm the crucial role played by Met in ovarian cancer and open new perspectives in the development of ovarian cancer targeted therapies.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21436615      PMCID: PMC3210202          DOI: 10.4161/cam.5.3.15258

Source DB:  PubMed          Journal:  Cell Adh Migr        ISSN: 1933-6918            Impact factor:   3.405


  10 in total

1.  Expression of HGF/NK4 in ovarian cancer cells suppresses intraperitoneal dissemination and extends host survival.

Authors:  Y Saga; H Mizukami; M Suzuki; M Urabe; A Kume; T Nakamura; I Sato; K Ozawa
Journal:  Gene Ther       Date:  2001-10       Impact factor: 5.250

2.  Suppression of urokinase expression and invasiveness by urinary trypsin inhibitor is mediated through inhibition of protein kinase C- and MEK/ERK/c-Jun-dependent signaling pathways.

Authors:  H Kobayashi; M Suzuki; Y Tanaka; Y Hirashima; T Terao
Journal:  J Biol Chem       Date:  2000-10-24       Impact factor: 5.157

Review 3.  Focal adhesion kinase and its signaling pathways in cell migration and angiogenesis.

Authors:  Xiaofeng Zhao; Jun-Lin Guan
Journal:  Adv Drug Deliv Rev       Date:  2010-11-29       Impact factor: 15.470

Review 4.  MET signalling: principles and functions in development, organ regeneration and cancer.

Authors:  Livio Trusolino; Andrea Bertotti; Paolo M Comoglio
Journal:  Nat Rev Mol Cell Biol       Date:  2010-12       Impact factor: 94.444

Review 5.  The role of focal-adhesion kinase in cancer - a new therapeutic opportunity.

Authors:  Gordon W McLean; Neil O Carragher; Egle Avizienyte; Jeff Evans; Valerie G Brunton; Margaret C Frame
Journal:  Nat Rev Cancer       Date:  2005-07       Impact factor: 60.716

6.  Loss of E-cadherin promotes ovarian cancer metastasis via alpha 5-integrin, which is a therapeutic target.

Authors:  Kenjiro Sawada; Anirban K Mitra; A Reza Radjabi; Vinay Bhaskar; Emily O Kistner; Maria Tretiakova; Sujatha Jagadeeswaran; Anthony Montag; Amy Becker; Hilary A Kenny; Marcus E Peter; Vanitha Ramakrishnan; S Diane Yamada; Ernst Lengyel
Journal:  Cancer Res       Date:  2008-04-01       Impact factor: 12.701

7.  AKT2, a putative oncogene encoding a member of a subfamily of protein-serine/threonine kinases, is amplified in human ovarian carcinomas.

Authors:  J Q Cheng; A K Godwin; A Bellacosa; T Taguchi; T F Franke; T C Hamilton; P N Tsichlis; J R Testa
Journal:  Proc Natl Acad Sci U S A       Date:  1992-10-01       Impact factor: 11.205

8.  An orally available small-molecule inhibitor of c-Met, PF-2341066, reduces tumor burden and metastasis in a preclinical model of ovarian cancer metastasis.

Authors:  Marion Zillhardt; James G Christensen; Ernst Lengyel
Journal:  Neoplasia       Date:  2010-01       Impact factor: 5.715

9.  Overexpression of the Met/HGF receptor in ovarian cancer.

Authors:  M F Di Renzo; M Olivero; D Katsaros; T Crepaldi; P Gaglia; P Zola; P Sismondi; P M Comoglio
Journal:  Int J Cancer       Date:  1994-09-01       Impact factor: 7.396

10.  Ligand-independent activation of c-Met by fibronectin and α(5)β(1)-integrin regulates ovarian cancer invasion and metastasis.

Authors:  A K Mitra; K Sawada; P Tiwari; K Mui; K Gwin; E Lengyel
Journal:  Oncogene       Date:  2010-11-29       Impact factor: 9.867

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.